Stabilization of thrombocytes at ambient temperatures

Information

  • Patent Grant
  • 12121022
  • Patent Number
    12,121,022
  • Date Filed
    Friday, May 26, 2023
    a year ago
  • Date Issued
    Tuesday, October 22, 2024
    23 days ago
Abstract
Provided herein are formulations and methods for the stabilization of one or more thrombocytes at ambient temperatures. Also provided are formulations and methods for the stabilization of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures. Further provided are articles of manufacture and kits and methods for substantially stable storage of one or more thrombocyte at ambient temperatures.
Description
BACKGROUND OF THE INVENTION
1. Technical Field

The present invention relates generally to stabilization of one or more thrombocytes at ambient temperatures. In particular, the invention relates to formulations, compositions, articles of manufacture, kits and methods for substantially stable storage of one or more metabolically-active thrombocytes at ambient temperatures.


BACKGROUND

Whole blood is a complex mixture of cells, nucleic acids, proteins and various other analytes. In particular, blood components include, but are not limited to: cells, such as leukocytes (monocytes, lymphocytes and granulocytes), erythrocytes, thrombocytes and circulating tumor cells; nucleic acid molecules, such a circulating-free DNA (cfDNA); polypeptides, such as lipoproteins, albumin and serum proteins, and other various analytes.


Thrombocytes or platelets are anucleated cells that play a key role in the clotting of blood. Thrombocytes are small, disc-like cells that circulate in mammalian blood and are involved in hemostasis. Thrombocytes secrete a wide variety of growth factors that assist in promoting blood clotting and tissue regeneration.


The level of circulating thrombocytes in a healthy individual is controlled within a physiological range of about (150-400)×103 per mm3. Suboptimal levels of thrombocytes (thrombocytopenia) can lead to excessive bleeding, whereas levels exceeding optimal concentrations can lead to the formation of thromboli (blood clots) that can obstruct blood vessels and can lead to higher risk of stroke, pulmonary embolus or myocardial infarction.


Circulating thrombocytes are typically present in an inactivated state, and are maintained in the inactivated state by factors produced by endothelial cells lining the blood vessel lumen. Upon disruption or injury to this endothelial layer, thrombocytes come in contact with collagen or von Wildebrand's factor, which activates the thrombocytes causing the thrombocytes to aggregate (i.e., clot). This activation and aggregation also may occur by the enzymatic activity of thrombin or in the presence of ADP. Upon activation, thrombocytes release the contents of alpha and dense granules that include growth factors and fibrinogen that assist in clot formation and help promote recruitment of fibroblasts to promote wound healing. Activated thrombocytes can be distinguished from inactivated thrombocytes by their more spherical/stellate shape.


The activation, aggregation and/or release of numerous growth factors and other intracellular components of thrombocytes during the collection of whole blood can greatly hinder the quantitation and analysis of these cells. The addition of various anti-coagulants to maintain an inactivated thrombocytes at ambient temperatures results in only about 13-52% inactivated thrombocytes at 24 hours making accurate quantitative analysis of total thrombocytes essentially impossible at this time point. Thus, there exists a need for improved formulations for and methods of stabilizing thrombocytes at ambient temperatures for a time sufficient for storage and shipping thrombocytes for research, diagnostic and therapeutic purposes.


SUMMARY OF THE INVENTION

The formulations, compositions and methods of the present invention advantageously provide for the stabilization of thrombocytes at ambient temperatures and these cells remain functional and retain the ability to be activated post-blood collection for a period of at least 24 hours, significantly increasing the time for storage and shipping of substantially stable thrombocytes for research, diagnostic and potential therapeutic applications. Disclosed herein in some embodiments, are formulations for substantially stable storage of one or more thrombocytes at ambient temperatures, wherein the one or more thrombocytes are stabilized for a period of at least six hours. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state. In some embodiments, the one or more thrombocytes are in a blood sample. In some embodiments, the one or more thrombocytes are in an inactivated state in a blood sample. In some embodiments, the one or more thrombocytes are isolated from a blood sample. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least nine hours. In some embodiments, the thrombocytes are stabilized in an inactivated state for a period of at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours. In some embodiments, the formulation comprises: (i) a pH buffer; (ii) an anti-coagulant; (iii) at least one non-reducing sugar or polyol; and (iv) a functionalized carbohydrate. In some embodiments, the formulation comprises a polyol selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol and inositol, and combinations thereof. In some embodiments, the polyol is a pentose polyol or a hexose polyol. In some embodiments, the pentose polyol is adonitol. In some embodiments, the functionalized carbohydrate is sucralfate or sucrose octasulfate. In some embodiments, the functionalized carbohydrate is sucrose octasulfate. In some embodiments, the non-reducing sugar is sucrose or trehalose. In some embodiments, the non-reducing sugar is trehalose. In some embodiments, the anticoagulant is EDTA or hirudin. In some embodiments, the pH buffer is 2× phosphate buffered saline or Tris-HCl.


In one aspect of the invention, formulations are provided for substantially stable storage of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures, wherein the one or more thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, the thrombocytes are stabilized in an inactivated state for a period of at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours. In certain embodiments, the formulation comprises (i) a pH buffer, (ii) an anticoagulant, (iii) at least one non-reducing sugar or polyol, and (iv) a functionalized carbohydrate. In some embodiments, the polyol is selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol inositol, and combinations thereof. In some embodiments the polyol is a pentose polyol or a hexose polyol. In some embodiments, the polyol is adonitol. In some embodiments, the functionalized carbohydrate is sucralfate or sucrose octasulfate. In some embodiments, the functionalized carbohydrate is sucrose octasulfate. In some embodiments, the non-reducing sugar is sucrose or trehalose. In some embodiments, the non-reducing sugar is trehalose. In some embodiments, the anticoagulant is EDTA or hirudin. In some embodiments, the anticoagulant is EDTA, the functionalized carbohydrate is sucralfate or sucrose octasulfate, and the non-reducing sugar is sucrose or trehalose. In yet other embodiments, the anticoagulant is EDTA, the functionalized carbohydrate is sucrose octasulfate and the non-reducing sugar is trehalose. In some embodiments, the pH buffer is 2× phosphate buffered saline or Tris-HCl. Disclosed herein, in some embodiments are formulations for substantially stable storage of one or more thrombocytes at ambient temperatures, comprising a halogenated disaccharide derivative and an anticoagulant, wherein the one or more thrombocytes are stabilized for a period of at least six hours. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state. In some embodiments, the one or more thrombocytes are in a blood sample. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state in a blood sample. In some embodiments, the one or more thrombocytes are isolated from a blood sample. In some embodiments, the anticoagulant is hirudin. In some embodiments, the halogenated disaccharide derivative is selected from the group consisting of sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichloronated maltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, 1,6-sichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside, and combinations thereof. In some embodiments, the formulation consists essentially of hirudin and sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside).


In some embodiments, there are provided formulations for substantially stable storage of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures, comprising a halogenated disaccharide derivative, wherein the one or more thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, the halogenated disaccharide derivative preferably is selected from the group consisting of sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichloronated maltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside and 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside, and more preferably the halogenated disaccharide derivative is sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside). In some embodiments, the formulations further comprise an anticoagulant, preferably hirudin. In some embodiments, the anticoagulant is hirudin. In some embodiments, the formulation consists essentially of hirudin and sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside).


Disclosed herein in some embodiments, are compositions of substantially, stably stored one or more thrombocytes comprising one or more thrombocytes admixed with a disclosed formulation. In some embodiments, the one or more thrombocytes are in a blood sample. In some embodiments, the one or more thrombocytes are isolated thrombocytes. In some embodiments, the one or thrombocytes are in an inactivated state.


Disclosed herein in some embodiments, are articles of manufacture, comprising a formulation described herein contained within a blood collection tube. In some embodiments, the blood collection tube is an evacuated blood collection tube.


Disclosed herein, in some embodiments, are kits comprising an article of manufacture described herein and a package insert.


Disclosed herein in some embodiments, are methods for substantially stable storage of one or more thrombocytes at ambient temperatures, comprising: admixing the one or more thrombocytes from a subject with a formulation provided herein, wherein the one or more thrombocyte is stabilized for a period of at least six hours. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state. In some embodiments, the one or more thrombocytes are in a blood sample from the subject. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state in a blood sample from the subject. In some embodiments, the one or more thrombocytes are isolated from a blood sample from the subject. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least nine hours. In some embodiments, the method further comprises activating the one or more thrombocyte in an inactivated state, by the addition of an activating agent to promote thrombocyte aggregation. In some embodiments, the activating agent is ADP. In some embodiments, the method further comprises activating the one or more thrombocyte by the addition of an activating agent to promote thrombocyte aggregation. In some embodiments, the activating agent is ADP. In some embodiments, the subject is an animal. In some embodiments, the subject is a mammal. In some embodiments, the mammal is a human.


Disclosed herein in some embodiments, are methods for substantially stable storage of one or more thrombocyte in an inactivated state in a blood sample at ambient temperatures, comprising, admixing a blood sample from a subject with a formulation provided herein, wherein the one or more thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least six hours. In some embodiments, the thrombocytes are stabilized in an inactivated state for a period of at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours. In some embodiments, the blood sample is admixed with the stabilization formulation at the time the blood sample is collected from the subject to substantially stabilize the one or more thrombocytes in the inactived state post collection from the subject. In some embodiments, the method further comprises activating the one or more thrombocytes by the additional of an activating agent. In some embodiments, the activating agent is ADP. In further embodiments of the methods, the subject is an animal, more preferably a mammal, and even more preferably a human.







DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to formulations, compositions, articles of manufacture, kits, and methods for substantially stable storage of one or more thrombocyte at ambient temperatures. In some embodiments, the one or more thrombocytes are stored in an inactivated, but activatable, state in a blood sample. In one aspect, the formulations described herein beneficially maintain the integrity of inactivated, metabolically active, thrombocytes that may be subsequently analyzed for activation or that may be used in therapeutic applications for promoting blood clotting in a patient.


As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, references to “the method” includes one or more methods, and/or steps of the type described herein which will become apparent to those persons skilled in the art upon reading this disclosure and so forth.


“About” as used herein when referring to a measurable value such as an amount, a temporal duration, and the like, is meant to encompass variations of ±20% or ±10%, or ±5%, or even ±1% from the specified value, as such variations are appropriate for the disclosed compositions or to perform the disclosed methods.


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All patents, patent applications and publications referred to herein are incorporated by reference in their entirety.


Formulations are provided, in some embodiments, for substantially stable storage of metabolically-active thrombocytes at ambient temperatures. In some embodiments, the thrombocytes are isolated from a blood sample. In some embodiments, the thrombocytes are in a blood sample. In some embodiments, the thrombocytes are inactivated. In certain embodiments, the thrombocyte stabilization formulations comprise a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functionalized carbohydrate. In certain other embodiments, the thrombocyte stabilization formulations comprise a pH buffer, an anticoagulant, a polyol and a functionalized carbohydrate. In certain other embodiments, the stabilization formulations comprise a pH buffer, an anticoagulant, a non-reducing sugar, and a functionalized carbohydrate. In still yet another embodiment, the stabilization formulations comprise a halogenated disaccharide derivative and an anticoagulant. In still yet another embodiment, the stabilization formulations comprise a halogenated disaccharide derivative, an anticoagulant, and a pH buffer. The formulations are capable of stabilizing at least 60%, 70%, 80% or even 90% inactivated, metabolically-active thrombocytes in a blood sample at ambient temperatures for a period of at least 6 hours, or at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours.


The term “ambient temperature” as used herein refers to common indoor room temperatures. In some embodiments, ambient temperature is 15 to 32° C. In some embodiments, ambient temperature is 20 to 27° C.


In another aspect of the present invention, formulations are provided for substantially stable storage of inactivated, metabolically-active thrombocytes in a blood sample at ambient temperatures. In certain embodiments, the thrombocyte stabilization formulations comprise a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functionalized carbohydrate. In certain other embodiments, the thrombocyte stabilization formulations comprise a pH buffer, an anticoagulant, a polyol, and a functionalized carbohydrate. In certain other embodiments, the stabilization formulations comprise a pH buffer, an anticoagulant, a non-reducing sugar, and a functionalized carbohydrate. In still yet another embodiment, the stabilization formulations comprise a halogenated disaccharide derivative and an anticoagulant. In still yet another embodiment, the stabilization formulations comprise a halogenated disaccharide derivative, an anticoagulant, and a pH buffer. The formulations are capable of stabilizing at least 60%, 70%, 80% or even 90% inactivated, metabolically-active thrombocytes in a blood sample at ambient temperatures for a period of at least 6 hours, or at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours.


In another aspect, compositions are provided herein in which a blood sample is admixed with a thrombocyte stabilization formulation to produce substantially stable one or more inactivated thrombocytes in a whole blood preparation. In still other embodiments, a composition comprising purified or substantially purified one or more thrombocyte admixed with a stabilization formulation of the present invention are provided.


Formulation Reagents

A. pH Buffers


According to certain embodiments, the herein described formulations and compositions for substantially stable storage of one or more thrombocytes include one or more pH buffers. In some embodiments, the pH buffer is any of a large number of compounds known in the art for their ability to resist changes in the pH of a solution, such as in an aqueous solution in which the pH buffer is present. Selection of one or more particular pH buffers for inclusion in a stable storage composition may be done based on the present disclosure and according to routine practices in the art, and may be influenced by a variety of factors including the pH that is desired to be maintained, the nature of the biological sample, the solvent conditions to be employed, the other components of the formulation to be used, and other criteria. For example, typically a pH buffer is employed at a pH that is within about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.0 pH unit of a proton dissociation constant (pKa) that is a characteristic of the buffer.


Non-limiting examples of pH buffers include citric acid, tartaric acid, malic acid, sulfosalicylic acid, sulfoisophthalic acid, oxalic acid, borate, CAPS (3-(cyclohexylamino)-1-propanesulfonic acid), CAPSO (3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid), EPPS (4-(2-hydroxyethyl)-1-piperazinepropanesulfonic acid), HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid), MES (2-(N-morpholino)ethanesulfonic acid), MOPS (3-(N-morpholino)propanesulfonic acid), MOPSO (3-morpholino-2-hydroxypropanesulfonic acid), PIPES (1,4-piperazinediethanesulfonic acid), TAPS (N-[tris(hydroxymethyl)methyl]-3-aminopropanesulfonic acid), TAPSO (2-hydroxy-3-[tris(hydroxymethyl)methylamino]-1-propanesulfonic acid), TES (N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid), bicine (N,N-bis(2-hydroxyethyl)glycine), tricine (N-[tris(hydroxymethyl)methyl]glycine), tris (tris(hydroxymethyl)aminomethane) and bis-tris (2-[bis(2-hydroxyethyl)amino]-2-(hydroxymethyl)-1,3-propanediol). In some embodiments, including any of those set forth in Table 1, have a pH of about 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8.0, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, or 9.0.


B. Polyols


Also as described herein, certain embodiments include at least one polyol in the composition for substantially stable storage of viable, inactivated thrombocytes in a whole blood sample at ambient temperatures. Polyols are polyhydric alcohols containing two or more hydroxyl groups and have the general formula H(CHOH)nH, wherein n is an integer selected from 2 to 7 inclusive. Polyols differ in chain length with most polyols having five- or six carbon chains being derived from pentoses (five-carbon sugars) and hexoses (six-carbon sugars); however shorter and longer carbon chain polyols also exist. Exemplary polyols include, but are not limited to, glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol and inositol. Selection of one or more particular polyols for inclusion in a substantially stable storage composition may be done based on the present disclosure and according to routine practices in the art, and may be influenced by a variety of factors including other formulation components. In certain embodiments, the polyol present in the formulation is a pentose polyol. In some embodiments, the polyol is adonitol. In some embodiments, the polyol is present at a concentration between 20-100 mM, or between about 25-75 mM. In some embodiments, the polyol is a pentose polyol and is present at a concentration between 20-100 mM, or between about 25-75 mM. In some embodiments, the polyol is adonitol and is present at a concentration between 20-100 mM, or between about 25-75 mM.


C. Disaccharide Derivatives


In certain embodiments, the formulations or compositions for substantially stable storage of one or more inactivated thrombocyte in a whole blood sample at ambient temperatures, including those in Table 1, include at least one halogenated disaccharide derivative. In some embodiments, the halogenated disaccharide derivative is a di- or tri-chlorinated disaccharide. In some embodiments, such di- or tri-chlorinated disaccharides unexpectedly are capable of substantially stable storage of inactivated thrombocytes either alone or in the presence of only a buffer. Halogenated disaccharide derivatives are known, e.g., see US Patent Publication No. 2014/0065062, and include sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside), trichloronated maltose, 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside, and 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside. Selection of one or more particular halogenated disaccharide derivative for inclusion in a substantially stable storage composition may be done based on the present disclosure and according to routine practices in the art, and may be influenced by a variety of factors including other formulation components. In some embodiments, the functionalized carbohydrate is sucralose and is present at about 1.0-50.0 mM. In some embodiments, the functionalized carbohydrate is sucralose and is present at about 10.0-30.0 mM. In some embodiments, the functionalized carbohydrate is sucralose and is present at about 25.0 mM.


D. Functionalized Carbohydrates


In some embodiments described herein, the formulations, including those in Table 1, include a functionalized carbohydrate. Exemplary functionalized carbohydrates include sucralfate or sucrose octasulfate and it will be appreciated that from the present disclosure the skilled person may select other functionalized carbohydrates for use in a stable storage formulations and compositions for viable, activatable, thrombocytes, as may vary based on the other components of the composition that are employed. In some embodiments, the concentration of functionalized carbohydrates in the present formulations and compositions, including those set forth in Table 1, is about 0.005-1.0 mM. In some embodiments, the concentration of functionalized carbohydrates in the present formulations and compositions, including those set forth in Table 1, is about 0.25-0.5 mM.


E. Non-Reducing Sugars


In some embodiments, the formulations and compositions for substantially stable storage of thrombocytes at ambient temperatures include at least one non-reducing sugar. In some embodiments, the formulations and compositions for substantially stable storage of viable, inactivated thrombocytes in a whole blood sample at ambient temperatures include at least one non-reducing sugar. As used herein, “non-reducing sugars” refers to carbohydrate molecules that lack a functional aldehyde group. Exemplary non-reducing sugars include sucrose and trehalose. In some embodiments, the non-reducing sugar is sucrose. In some embodiments, the non-reducing sugar is trehalose. In some embodiments, the trehalose is present at a concentration of about 1.0-50 mM. In some embodiments, the trehalose is present at a concentration of about 10.0-30 mM. In some embodiments, the trehalose is present at a concentration of about 25 mM.


F. Anticoagulants


In some embodiments, an anticoagulant is included in the presently described formulations or compositions. Such anticoagulants are known in the art. Exemplary anticoagulants include ethylenediaminetetraacetic acid (EDTA), hirudin, heparin, and sodium citrate. In some embodiments, the anticoagulant is hirudin. In some embodiments, the hirudin is present at a concentration of about 1.0-50 μg/mL. In some embodiments, the hirudin is present at a concentration of about 1.0-25 μg/mL. In some embodiments, the hirudin is present at a concentration of about 10-20 μg/mL.


Exemplary Formulations for Stabilization of Thrombocytes at Ambient Temperatures

In some embodiments, the formulations, compositions and methods of the present invention advantageously provide for the substantially stable storage of thrombocytes at ambient temperatures for a period of at least six hours. In some embodiments, the formulations, compositions and methods of the present invention advantageously provide for the substantially stable storage of thrombocytes in their natural circulating, inactivated state in a blood sample at ambient temperatures, wherein the cells retain the ability to be activated post collection for a period of at least six hours. In other embodiments, at least 90% of the thrombocytes are stabilized in an inactivated state for a period of at least six hours. In other embodiments, the thrombocytes are stabilized in an inactivated state for a period of at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours.


In certain embodiments, the formulations for the substantially stable storage of thrombocytes at ambient temperatures comprise a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functionalized carbohydrate. In certain embodiments, the stabilization formulations comprise a pH buffer, an anticoagulant, a polyol, and a functionalized carbohydrate. In certain embodiments, the formulations for the substantially stable storage of thrombocytes comprise a pH buffer, an anticoagulant, a non-reducing sugar, and a functionalized carbohydrate. In some embodiments, the formulations for the substantially stable storage of thrombocytes comprise a halogenated disaccharide derivative, and an anticoagulant, and may further comprise a pH buffer. In some embodiments, the anti-coagulant is sprayed and dried on the blood collection tube, container, or vessel prior to collection of the blood sample from the subject. In some embodiments, the anti-coagulant is added directly to the formulations described herein.


In certain embodiments, the pH buffer is Tris-HCl, the polyol is a pentose alcohol, the non-reducing sugar is trehalose, the anticoagulant is EDTA or hirudin, and the functionalized carbohydrate is sucrose octasulfate. In certain embodiments, the pH buffer is Tris-HCl, the polyol is adonitol, the non-reducing sugar is the D+ isomer of trehalose, the anticoagulant is EDTA or hirudin, and the functionalized carbohydrate is sucrose octasulfate. In certain embodiments, the pH buffer is Tris-HCl, the polyol is adonitol, the non-reducing sugar is the D+ isomer of trehalose, the anticoagulant is hirudin, and the functionalized carbohydrate is sucrose octasulfate. In some embodiments, the disaccharide derivative is a halogenated disaccharide and the anticoagulant is hirudin. In some embodiments, the halogenated disaccharide is sucralose and the anticoagulant is hirudin.


In some embodiments, the formulations for the substantially stable storage of inactivated thrombocytes at ambient temperatures include the exemplary formulations provided in Table 1.









TABLE 1







Exemplary Formulations for Stabilizing Inactivated,


Metabolically-active Thrombocytes in a Human


Blood Sample at Ambient Temperatures













Tris-


Sucrose




HCl
Adonitol
Trehalose
Octasulfate
Sucralose


Formulation
(mM)
(mM)
(mM)
(mM)
(mM)















A
2.5
100

1.0



B
2.5
50
25.0
1.0


C
2.5

25.0
1.0


D
2.5
50
25.0
0.5


E
2.5



25


F




25









Methods for Preparing Exemplary Formulations

In some embodiments, the exemplary Formulations A-F of Table 1 are prepared using materials commercially available from suppliers and preparing such formulations is accomplished using the methods disclosed herein as well as other methods known to those skilled in the art.


In some embodiments, pre-weighed solid components are added to a suitable vessel, such as a square bottle, to which the aqueous components are added. The reaction mixture is agitated, e.g., by shaking, until the solid components have completely dissolved and then the pH of the mixture is adjusted to the desired pH using a suitable acid, e.g., hydrochloric acid. The resulting formulations are then sterilized, e.g., using a 0.22 micron filter, and stored at room temperature.


In one example, a 50 mL preparation of a 20× Formula A is prepared as follows: 15.2034 gr of adonitol (Calbiochem, catalogue #121739) and 1.251 g sucrose octasulfate potassium salt (Toronto Research Chemicals, catal,ogue #S69900) are added to a square bottle. A 30 mL volume of water is added, followed by the addition of 2.5 mL of Tris-HCl (Invitrogen, catalogue #15567-027). Additional water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved, and hydrochloric acid is added to adjust the pH to 7.51. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.


In another example, a 50 mL preparation of a 20× Formula B is prepared as follows: 7.5994 g of adonitol, 9.4997 g D-(+)-trehalose dihydrate (Fluka, catalogue #90210), and 1.25 g sucrose octasulfate potassium salt are added to a square bottle. A 30 mL volume of water is added, followed by the addition of 2.5 mL of Tris-HCl (Invitrogen, catalogue #15567-027). Additional water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved, and hydrochloric acid is added to adjust the pH to 7.51. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.


In another example, a 50 mL preparation of a 20× Formula C is prepared as follows: 9.5003 g D-(+)-trehalose dehydrate and 1.2502 g sucrose octasulfate potassium salt are added to a square bottle. A 30 mL volume of water is added, followed by the addition of 2.5 mL of Tris-HCl (Invitrogen, catalogue #15567-027). Additional water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved, and hydrochloric acid is added to adjust the pH to 7.52. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.


In another example, a 50 mL preparation of a 20× Formula D is prepared as follows: 7.5994 g of adonitol, 9.5003 g D-(+)-trehalose dihydrate and 0.625 g sucrose octasulfate potassium salt. A 30 mL volume of water is added, followed by the addition of 2.5 mL of Tris-HCl (Invitrogen, catalogue #15567-027). Additional water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved, and hydrochloric acid is added to adjust the pH to 7.51. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.


In another example, a 50 mL preparation of a 20× Formula E is prepared as follows: 9.9997 g of sucralose (Sigma, catalogue #69293) is added to a square bottle. A 30 mL volume of water is added, followed by the addition of 2.5 mL of Tris-HCl (Invitrogen, catalogue #15567-027). Additional water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved and hydrochloric acid is added to adjust the pH to 7.54. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.


In another example, a 50 mL preparation of a 20× Formula F is prepared as follows: 9.9993 g of sucralose (Sigma, catalogue #69293) is added to a square bottle. Water is added to qc the formulation to a final total volume of 50 mL. The mixture is shaken until fully dissolved, providing a solution having a pH of 7.54. The solution is sterile filtered (0.22 μm pore size) under vacuum to yield the resulting formulation.


Purified Stabilized Thrombocytes

In some embodiments, the substantially stabilized one or more thrombocytes in a blood sample at ambient temperatures are purified using well known methods employed by those skilled in the art. Apparatus and kits for purifying thrombocytes from blood are well known (e.g., see U.S. Pat. Nos. 5,234,593; 6,315,706 and 7,708,152). In certain embodiments, the thrombocytes are purified using a bag PC (platelet concentrate) prepared after collection of blood in a bag and the apheresis PC obtained by the use of a component blood collecting device. These methods separate thrombocytes from blood using centrifugal separation. In some embodiments, substantially stabilized, intact, metabolically active viable cells are advantageously purified by affinity chromatography or by fluorescence activated cell sorting (FACS) analysis using antibodies generated against a native wild type membrane proteins and receptors, and which method is not possible using other storage formulations that denature these cellular proteins.


In some embodiments, the purified one or more thrombocyte are subsequently stored in the formulations described herein for extended periods before analysis or use.


Articles of Manufacture

In certain embodiments, articles of manufacture are provided, which comprise a formulation provided herein, contained within a suitable blood collection tube, container or vessel. In some embodiments, the formulation is selected from those set forth in Table 1. In some embodiments, these articles of manufacture are used for substantially stable storage of one or more blood component by stabilizing one or more blood component at the time of blood collection. In certain embodiments, the blood collection tube is an evacuated blood tube having less than atmospheric pressure to withdraw a predetermined volume of whole blood. In some embodiments, these articles of manufacture are used in the kits and methods described herein.


Kits

In certain embodiments, there are provided kits comprising any one of the articles of manufacture described herein and a package insert. In some embodiments, the components of the kit are supplied in a packaging means, such as a compartmentalized plastic enclosure, preferably with a hermetically sealable cover so that the contents of the kit can be sterilized and sealed for storage.


Methods for Substantially Stable Storage of One or More Thrombocyte in a Blood Sample at Ambient Temperatures

Described herein, in some embodiments, are methods for substantially stable storage of one or more thrombocyte at ambient temperatures. In some embodiments, the methods are for substantially stable storage of one or more thrombocytes in an inactivated state in a blood sample at ambient temperatures.


In certain embodiments, the methods comprise admixing a blood sample with a formulation for substantially stable storage of one or more thrombocyte at ambient temperatures for a period of at least six hours. In some embodiments, the one or more thrombocytes are isolated from a blood sample. In some embodiments, the one or more thrombocytes are stabilized in an inactivated state. In some embodiments, at least 90% of the thrombocytes remain in an inactivated state for a period of at least six hours. In other embodiments, the thrombocytes are stabilized in an inactivated state for a period of at least 7 hours, at least 8 hours, at least 9 hours, at least 10 hours, at least 11 hours, at least 12 hours, at least 13 hours, at least 14 hours, at least 15 hours, at least 16 hours, at least 17 hours, at least 18 hours, at least 19 hours, at least 20 hours, at least 21 hours, at least 22 hours, at least 23 hours or at least 24 hours. In certain embodiments, the formulation is one of the formulations set forth in Table 1.


In certain embodiments, the methods comprise admixing a blood sample with a formulation for substantially stable storage of viable thrombocytes, wherein the formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, a polyol and a functionalized carbohydrate. In certain embodiments, the thrombocyte stabilization formulations comprise a pH buffer, an anticoagulant, a polyol, and a functionalized carbohydrate. In certain embodiments, the stabilization formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, and a functionalized carbohydrate. In still yet another embodiment, the stabilization formulation comprises a halogenated disaccharide derivative and an anticoagulant. In still yet another embodiment, the stabilization formulation comprises a halogenated disaccharide derivative and an anticoagulant furthers comprise a pH buffer. In certain embodiments, the formulation is one of the formulations set forth in Table 1.


In certain embodiments, the methods comprise admixing a blood sample with a formulation for substantially stable storage of viable, activatable thrombocytes in a blood sample, wherein the formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, a polyol, and a functionalized carbohydrate. In certain embodiments, the thrombocyte stabilization formulation comprises a pH buffer, an anticoagulant, polyol, and a functionalized carbohydrate. In certain other embodiments, the stabilization formulation comprises a pH buffer, an anticoagulant, a non-reducing sugar, and a functionalized carbohydrate. In still yet another embodiment, the stabilization formulation comprises a halogenated disaccharide derivative and an anticoagulant. In still yet another embodiment, the stabilization formulation further comprises a pH buffer. In certain embodiments, the formulation is one of the formulations set forth in Table 1.


Blood collection tubes, bags, containers and vessels are well-known in the art and have been employed by medical practitioners for decades. Blood collected for substantially stable storage of one or more blood component may be obtained from a subject, donor, or patient using any method or apparatus commonly employed by those skilled in the art such as venipuncture or finger prick. In some embodiments, when the blood is collected by venipuncture, a formulation described herein is located inside the blood collection tube, e.g., an evacuated tube (Vacutainer, Becton Dickenson or Vacuette, Greiner) at the time that the blood sample is obtained from the donor or patient. In some embodiments, the stabilization formulation is added to an already obtained whole blood sample, preferably immediately or shortly after it is withdrawn.


In some embodiments, the methods described herein use the articles of manufacture and kits disclosed.


The following Examples are presented by way of illustration and not limitation.


Example 1: Stabilization of Inactive Thrombocytes in a Human Blood Sample for a Period of at Least 22 Hours at Ambient Temperature

This Example describes formulations of the present invention for stabilizing inactivated thrombocytes that remain capable of being activated after being stored for a period of 22 hours at ambient temperatures.


Whole blood samples were collected from six human donors using commercially available hirudin-coated collection tubes (Roche Diagnostics), the blood samples were pooled and within three hours of collection, blood samples were processed. A 300 μL aliquot of each whole blood sample was transferred to an Eppendorf tube at a 1:20 ratio with 15 μL of stabilizer formulation A, B, C, or D of Table 1, either prior to or following the addition of the stabilizer formulation, and the mixtures were kept at ambient temperatures for predetermined time periods before being analyzed. An equal volume of whole blood was added to each control sample, and each sample was stored at room temperature in the absence of the stabilizer formulation and processed in parallel with the test samples.


To 300 μL of each mixture and control, 300 μL of NaCl 0.9% and 20 μL of the provided ADP solution was added to promote activation of the thrombocytes and the samples were analyzed using a multiplate analyzer (Roche Diagnostics). Thrombocyte activity in each condition was measured immediately after sample set-up (Time 0) using the multiplate analyzer and ADP test according to the manufacturer's instructions. Thrombocyte activity was also measured at 3 hour, 6 hour, 9 hour and 22 hour time points. Thrombocyte activity in each condition was normalized to its Time 0 measurement. Data from the six donors were then averaged. The data are shown in Table 2.









TABLE 2







Stabilization of Viable, Activatable Thromobocytes


in a Human Blood Sample for at Least 22 Hours












Time

Formulation
Formulation
Formulation
Formulation


(hr)
Control
A
B
C
D















0
100*
100
100
100
100


3
93
110
112
96
98


6
82
107
111
101
95


9
77
115
114
101
93


22
59
91
92
74
90





*Values are shown as present activity remaining relative to Time 0






As shown in Table 2, after the 9 hour incubation period, the mean decrease in thrombocyte activity in the NF control condition was −23% compared with +15%, +14%, +1% and −7% for Formulations A, B, C, and D of Table 2, respectively. After a 22 hour incubation period, significant thrombocyte activity was still detected with a mean decrease in thrombocyte activity in the NF control condition of −41%, compared with −9%, −8%, −26% and −10% for Formulations A, B, C, and D of Table 2, respectively.


Formulations of Table 1 comprising a halogenated disaccharide derivative, sucralose, were characterized as described above, and also were identified as possessing stabilizing thrombocyte activity in whole blood for at least 22 hours (Table 3). In this study, these formulations, as set forth in Table 1, were incorporated into hirudin vacuum blood collection tubes prior to blood draw.









TABLE 3







Stabilization of Viable, Activatable Thromobocytes


in a Human Blood Sample for at Least 22 Hours












Formulation
Time 0
3 Hours
6 Hours
9 Hours
22 Hours















Control
100
89
69
58
60


E
100
100
99
98
97


F
100
94
87
80
73





*Values are shown as present activity remaining relative to Time 0






During room temperature blood incubation, thrombocyte activity in the NF control condition decreased by −40% by the 22 hour time point, compared with −3% for Formula E and −27% for Formula F of Table 1.


Unless the context requires otherwise, throughout the present specification and claims, the word “comprise” and variations thereof, such as, “comprises” and “comprising,” which is used interchangeably with “including,” “containing,” or “characterized by,” is inclusive or open-ended language and does not exclude additional, unrecited elements or method steps. The phrase “consisting of” excludes any element, step, or ingredient not specified in the claim. The phrase “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. The present disclosure contemplates embodiments of the invention compositions and methods corresponding to the scope of each of these phrases. Thus, a composition or method comprising recited elements or steps contemplates particular embodiments in which the composition or method consists essentially of or consists of those elements or steps.


Reference throughout this specification to “one embodiment” or “an embodiment” or “an aspect” means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment of the present invention. Thus, the appearances of the phrases “in one embodiment” or “in an embodiment” in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.


The various embodiments described above can be combined to provide further embodiments. These and other changes can be made to the embodiments in light of the above-detailed description. In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.


From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not limited except as by the appended claims.

Claims
  • 1. A method for stabilizing at least one component of a blood sample at ambient temperatures, the method comprising: admixing a blood sample from a subject with a composition to form a mixture, wherein the composition comprises a halogenated disaccharide derivative at about 0.1 μM to about 50 μM and an anticoagulant; andstoring the mixture at ambient temperatures for at least six hours.
  • 2. The method of claim 1, wherein the halogenated disaccharide derivative is a di- or tri-chlorinated disaccharide.
  • 3. The method of claim 1, wherein the halogenated disaccharide derivative is sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside); trichloronated maltose; 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside; 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside; or any combinations thereof.
  • 4. The method of claim 1, wherein the anticoagulant is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), hirudin, heparin, and sodium citrate, or any combination thereof.
  • 5. The method of claim 1, wherein the composition further comprises a pH buffer comprising Tris-HCl, citric acid, or 2× phosphate buffered saline.
  • 6. The method of claim 1, wherein the composition further comprises a polyol selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol, and inositol, or any combinations thereof.
  • 7. The method of claim 6, wherein the polyol is present at a concentration ranging from about 90 mM to about 2.5 M.
  • 8. The method of claim 1, wherein the composition further comprises a functionalized carbohydrate selected from the group consisting of sucralfate and sucrose octasulfate, or a combination thereof.
  • 9. The method of claim 1, wherein the composition further comprises a non-reducing sugar selected from the group consisting of sucrose and trehalose, or a combination thereof.
  • 10. The method of claim 1, wherein the pH of the composition is in the range of about 4.0 to about 9.0.
  • 11. The method of claim 1, wherein the at least one component of a blood sample is one or more of a cell, a nucleic acid molecule, a peptide or polypeptide, or any combination thereof.
  • 12. A composition for stabilizing at least one component of a blood sample at ambient temperatures, the composition comprising: (i) a pH buffer;(ii) an anticoagulant; and(iii) a halogenated disaccharide derivative;wherein the pH of the composition is in the range of about 4.0 to about 9.0.
  • 13. The composition of claim 12, wherein the pH buffer comprises Tris-HCl, citric acid, or 2× phosphate buffered saline.
  • 14. The composition of claim 12, wherein the anticoagulant is selected from the group consisting of ethylenediaminetetraacetic acid (EDTA), hirudin, heparin, and sodium citrate, or any combination thereof.
  • 15. The composition of claim 12, wherein the halogenated disaccharide derivative is a di- or tri-chlorinated disaccharide.
  • 16. The composition of claim 12, wherein the halogenated disaccharide derivative is sucralose (1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside); trichloronated maltose; 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monododecanoate-α-D-galactopyranoside; 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-6-O-monotetradecanoate-α-D-galactopyranoside; or any combinations thereof.
  • 17. The composition of claim 12, wherein the composition further comprises a polyol selected from the group consisting of glycol, glycerol, erythritol, threitol, arabitol, xylitol, ribitol, adonitol, mannitol, sorbitol, galactitol, fucitol, iditol, and inositol, or any combinations thereof.
  • 18. The composition of claim 17, wherein the polyol is present at a concentration ranging from about 90 mM to about 2.5 M.
  • 19. The composition of claim 12, wherein the composition further comprises a functionalized carbohydrate selected from the group consisting of sucralfate and sucrose octasulfate, or a combination thereof.
  • 20. The composition of claim 12, wherein the composition further comprises a non-reducing sugar selected from the group consisting of sucrose and trehalose, or a combination thereof.
  • 21. A blood collection tube comprising the composition of claim 12.
CROSS-REFERENCE

This application is a continuation application of U.S. patent application Ser. No. 15/316,677, filed Dec. 6, 2016, which is a U.S. National Phase Application of International Patent Application No. PCT/US2015/034967, filed Jun. 9, 2015, which claims the benefit of U.S. Provisional Application No. 62/010,151, filed Jun. 10, 2014, all of which are incorporated by reference herein in their entirety.

US Referenced Citations (334)
Number Name Date Kind
3673158 Arthur et al. Jun 1972 A
4024548 Alonso et al. May 1977 A
4040785 Kim et al. Aug 1977 A
4127502 Li et al. Nov 1978 A
4185964 Lancaster Jan 1980 A
4257958 Powell Mar 1981 A
4264560 Natelson Apr 1981 A
4342740 Narra et al. Aug 1982 A
4451569 Kobayashi et al. May 1984 A
4473552 Jost Sep 1984 A
4683195 Mullis et al. Jul 1987 A
4683202 Mullis Jul 1987 A
4800159 Mullis et al. Jan 1989 A
4801428 Homolko et al. Jan 1989 A
4806343 Carpenter et al. Feb 1989 A
4842758 Crutzen Jun 1989 A
4889818 Gelfand et al. Dec 1989 A
4891319 Roser Jan 1990 A
4898813 Albarella et al. Feb 1990 A
4933145 Uchida et al. Jun 1990 A
4962020 Tabor et al. Oct 1990 A
4962022 Fleming et al. Oct 1990 A
4965188 Mullis et al. Oct 1990 A
4978688 Louderback Dec 1990 A
5039704 Smith et al. Aug 1991 A
5047342 Chatterjee Sep 1991 A
5071648 Rosenblatt Dec 1991 A
5078997 Hora et al. Jan 1992 A
5079352 Gelfand et al. Jan 1992 A
5089407 Baker et al. Feb 1992 A
5096670 Harris et al. Mar 1992 A
5096744 Takei et al. Mar 1992 A
5098893 Franks et al. Mar 1992 A
5147803 Enomoto Sep 1992 A
5198353 Hawkins et al. Mar 1993 A
5200399 Wettlaufer et al. Apr 1993 A
5240843 Gibson et al. Aug 1993 A
5242792 Rudolph et al. Sep 1993 A
5270179 Chatterjee Dec 1993 A
5290765 Wettlaufer et al. Mar 1994 A
5315505 Pratt et al. May 1994 A
5351801 Markin et al. Oct 1994 A
5374553 Gelfand et al. Dec 1994 A
5397711 Finckh Mar 1995 A
5403706 Wilk et al. Apr 1995 A
5409818 Davey et al. Apr 1995 A
5418141 Zweig et al. May 1995 A
5428063 Barak et al. Jun 1995 A
5436149 Barnes Jul 1995 A
5455166 Walker Oct 1995 A
5496562 Burgoyne Mar 1996 A
5498523 Tabor et al. Mar 1996 A
5512462 Cheng Apr 1996 A
5516644 Yamauchi et al. May 1996 A
5529166 Markin et al. Jun 1996 A
5541290 Harbeson et al. Jul 1996 A
5556771 Shen et al. Sep 1996 A
5593824 Treml et al. Jan 1997 A
5614365 Tabor et al. Mar 1997 A
5614387 Shen et al. Mar 1997 A
5684045 Smith et al. Nov 1997 A
5705366 Backus Jan 1998 A
5728822 Macfarlane Mar 1998 A
5741462 Nova et al. Apr 1998 A
5751629 Nova et al. May 1998 A
5763157 Treml et al. Jun 1998 A
5777099 Mehra Jul 1998 A
5777303 Berney Jul 1998 A
5779983 Dufresne et al. Jul 1998 A
5789172 Still et al. Aug 1998 A
5789414 Lapidot et al. Aug 1998 A
5798035 Kirk et al. Aug 1998 A
5814502 Hoeltke et al. Sep 1998 A
5827874 Meyer et al. Oct 1998 A
5834254 Shen et al. Nov 1998 A
5837546 Allen et al. Nov 1998 A
5856102 Bierke-Nelson et al. Jan 1999 A
5861251 Park et al. Jan 1999 A
5863799 Hengstenberg Jan 1999 A
5874214 Nova et al. Feb 1999 A
5876992 De Rosier et al. Mar 1999 A
5914272 Dufresne et al. Jun 1999 A
5918273 Horn Jun 1999 A
5939259 Harvey et al. Aug 1999 A
5945515 Chomczynski Aug 1999 A
5948614 Chatterjee Sep 1999 A
5955448 Colaco et al. Sep 1999 A
5985214 Stylli et al. Nov 1999 A
5991729 Barry et al. Nov 1999 A
6013488 Hayashizaki Jan 2000 A
6015668 Hughes et al. Jan 2000 A
6017496 Nova et al. Jan 2000 A
6025129 Nova et al. Feb 2000 A
6037168 Brown Mar 2000 A
6050956 Ikegami et al. Apr 2000 A
6057117 Harrison et al. May 2000 A
6057159 Lepre May 2000 A
6071428 Franks et al. Jun 2000 A
6090925 Woiszwillo et al. Jul 2000 A
6124089 Ryan Sep 2000 A
6127155 Gelfand et al. Oct 2000 A
6143817 Hallam et al. Nov 2000 A
6153412 Park et al. Nov 2000 A
6153618 Schultz et al. Nov 2000 A
6156345 Chudzik et al. Dec 2000 A
6166117 Miyazaki Dec 2000 A
6168922 Harvey et al. Jan 2001 B1
6197229 Ando et al. Mar 2001 B1
6204375 Lader Mar 2001 B1
6221599 Hayashizaki Apr 2001 B1
6242235 Shultz et al. Jun 2001 B1
6251599 Chen et al. Jun 2001 B1
6258930 Gauch et al. Jul 2001 B1
6284459 Nova et al. Sep 2001 B1
6294203 Burgoyne Sep 2001 B1
6294338 Nunomura Sep 2001 B1
6310060 Barrett et al. Oct 2001 B1
6313102 Colaco et al. Nov 2001 B1
6322983 Burgoyne Nov 2001 B1
6323039 Dykens et al. Nov 2001 B1
6329139 Nova et al. Dec 2001 B1
6331273 Nova et al. Dec 2001 B1
6352854 Nova et al. Mar 2002 B1
6366440 Kung Apr 2002 B1
6372428 Nova et al. Apr 2002 B1
6372437 Hayashizaki Apr 2002 B2
6380858 Yarin et al. Apr 2002 B1
6416714 Nova et al. Jul 2002 B1
6417185 Goff et al. Jul 2002 B1
6426210 Franks et al. Jul 2002 B1
6440966 Barrett et al. Aug 2002 B1
6447726 Delucas et al. Sep 2002 B1
6447804 Burgoyne Sep 2002 B1
6448245 Depetrillo et al. Sep 2002 B1
RE37872 Franks et al. Oct 2002 E
6458556 Hayashizaki Oct 2002 B1
6465231 Harrison et al. Oct 2002 B2
6475716 Seki Nov 2002 B1
6489344 Nuss et al. Dec 2002 B1
6503411 Franks et al. Jan 2003 B1
6503702 Stewart Jan 2003 B1
6528309 Levine Mar 2003 B2
6534483 Bruno et al. Mar 2003 B1
6535129 Petrick Mar 2003 B1
6602718 Augello et al. Aug 2003 B1
6608632 Daly et al. Aug 2003 B2
6610531 Mateczun et al. Aug 2003 B1
6617170 Augello et al. Sep 2003 B2
6627226 Burgoyne et al. Sep 2003 B2
6627398 Wilusz et al. Sep 2003 B1
6638945 Gibson Oct 2003 B1
6645717 Smith et al. Nov 2003 B1
6649406 Williams et al. Nov 2003 B1
6653062 Depablo et al. Nov 2003 B1
6664099 Worrall Dec 2003 B1
6667167 Sorensen et al. Dec 2003 B1
6682730 Mickle et al. Jan 2004 B2
6689353 Wang et al. Feb 2004 B1
6696028 Bara Feb 2004 B2
6746841 Fomovskaia et al. Jun 2004 B1
6746851 Tseung et al. Jun 2004 B1
6750059 Blakesley et al. Jun 2004 B1
6776959 Helftenbein Aug 2004 B1
6787305 Li et al. Sep 2004 B1
6800632 Nuss et al. Oct 2004 B2
6803200 Xia et al. Oct 2004 B2
6821479 Smith et al. Nov 2004 B1
6821789 Augello et al. Nov 2004 B2
6852833 Machida et al. Feb 2005 B1
6858634 Asrar et al. Feb 2005 B2
6861213 Oelmuller et al. Mar 2005 B2
6862789 Hering et al. Mar 2005 B1
6872357 Bronshtein et al. Mar 2005 B1
6896894 Brody et al. May 2005 B2
6919172 Depablo et al. Jul 2005 B2
6942964 Ward et al. Sep 2005 B1
6949544 Bethiel et al. Sep 2005 B2
6949547 Nuss et al. Sep 2005 B2
7001770 Atencio et al. Feb 2006 B1
7001905 Biwersi et al. Feb 2006 B2
7011825 Yamazaki et al. Mar 2006 B2
7037918 Nuss et al. May 2006 B2
7045519 Nuss et al. May 2006 B2
7049065 Hayashizaki May 2006 B2
7083106 Albany Aug 2006 B2
7098033 Chen et al. Aug 2006 B2
7101693 Cicerone et al. Sep 2006 B2
7129242 Yoshitaka et al. Oct 2006 B2
7142987 Eggers Nov 2006 B2
7150980 Lapidot et al. Dec 2006 B1
7169584 Ward et al. Jan 2007 B2
7169816 Barrett et al. Jan 2007 B2
RE39497 Franks et al. Feb 2007 E
7172999 Mattern et al. Feb 2007 B2
7258873 Truong-Le et al. Aug 2007 B2
7270953 Hollaender et al. Sep 2007 B2
7282371 Helftenbein Oct 2007 B2
7326418 Franzoso et al. Feb 2008 B2
7384603 Klein et al. Jun 2008 B2
7425557 Nuss et al. Sep 2008 B2
7476754 Herradon et al. Jan 2009 B2
7521460 Langham et al. Apr 2009 B2
7592455 Brookings et al. Sep 2009 B2
7728013 Blatt et al. Jun 2010 B2
7745663 Isshiki et al. Jun 2010 B2
7795256 Alexander et al. Sep 2010 B2
7803839 Aay et al. Sep 2010 B2
7846703 Kobayashi et al. Dec 2010 B2
7897624 Yan et al. Mar 2011 B2
7919294 Franco et al. Apr 2011 B2
7932266 Garcia et al. Apr 2011 B2
7972828 Ward et al. Jul 2011 B2
8143271 Ibrahim et al. Mar 2012 B2
RE43389 Helftenbein May 2012 E
8178555 Chang et al. May 2012 B2
8378108 Corkey et al. Feb 2013 B2
8394822 Hutchings et al. Mar 2013 B2
8440665 Corkey et al. May 2013 B2
8492427 Gancia et al. Jul 2013 B2
8519125 Whitney et al. Aug 2013 B2
8530480 Kamenecka et al. Sep 2013 B2
8598360 Corkey et al. Dec 2013 B2
8642584 Aftab et al. Feb 2014 B2
8664244 Chen Mar 2014 B2
8827874 Nishimura Sep 2014 B2
8900856 Muller-Cohn et al. Dec 2014 B2
9078426 Muller-Cohn et al. Jul 2015 B2
9376709 Whitney et al. Jun 2016 B2
20010038858 Roser et al. Nov 2001 A1
20020039771 Peters et al. Apr 2002 A1
20020055118 Eym May 2002 A1
20020076819 Bowman et al. Jun 2002 A1
20020081565 Barnea et al. Jun 2002 A1
20020094533 Hess et al. Jul 2002 A1
20020103086 Asrar et al. Aug 2002 A1
20020182258 Lunsford et al. Dec 2002 A1
20020197628 Stewart Dec 2002 A1
20030022148 Seki Jan 2003 A1
20030031697 Chudzik et al. Feb 2003 A1
20030059468 Mattern et al. Mar 2003 A1
20030091971 Xia et al. May 2003 A1
20030119042 Franco et al. Jun 2003 A1
20030129755 Sadler et al. Jul 2003 A1
20030138805 Loffert et al. Jul 2003 A1
20030157088 Elliott et al. Aug 2003 A1
20030162284 Dordick et al. Aug 2003 A1
20030163608 Tiwary et al. Aug 2003 A1
20030165482 Rolland et al. Sep 2003 A1
20030175232 Elliott et al. Sep 2003 A1
20030199446 Bunger et al. Oct 2003 A1
20030215369 Eggers et al. Nov 2003 A1
20040014068 Burgoyne Jan 2004 A1
20040058349 Van Ness et al. Mar 2004 A1
20040101966 Davis et al. May 2004 A1
20040110267 Sundar Jun 2004 A1
20040121420 Smith Jun 2004 A1
20040121432 Klein et al. Jun 2004 A1
20040142475 Barman et al. Jul 2004 A1
20040208792 Linton et al. Oct 2004 A1
20040228794 Weller et al. Nov 2004 A1
20040241713 Mirzabekov et al. Dec 2004 A1
20050026181 Davis et al. Feb 2005 A1
20050053911 Greener et al. Mar 2005 A1
20050084481 Hand et al. Apr 2005 A1
20050086822 Frisner et al. Apr 2005 A1
20050090009 Cormier et al. Apr 2005 A1
20050112610 Lee et al. May 2005 A1
20050186254 Roser et al. Aug 2005 A1
20050196824 Fisher et al. Sep 2005 A1
20050227269 Lloyd et al. Oct 2005 A1
20050251501 Phillips et al. Nov 2005 A1
20050276728 Muller-Cohn et al. Dec 2005 A1
20060014177 Hogan et al. Jan 2006 A1
20060099567 Muller-Cohn et al. May 2006 A1
20060127415 Mayeresse Jun 2006 A1
20060147944 Chomczynski Jul 2006 A1
20060177855 Utermohlen et al. Aug 2006 A1
20060183687 Cory et al. Aug 2006 A1
20060193968 Keogh et al. Aug 2006 A1
20060198891 Ravenelle et al. Sep 2006 A1
20060210429 Hunsley et al. Sep 2006 A1
20060293212 Griese et al. Dec 2006 A1
20070020289 Mattern et al. Jan 2007 A1
20070043216 Bair et al. Feb 2007 A1
20070048726 Baust et al. Mar 2007 A1
20070073039 Chisari Mar 2007 A1
20070117173 Levison et al. May 2007 A1
20070135528 Butler et al. Jun 2007 A1
20070212760 Lapidot et al. Sep 2007 A1
20070243178 Ho et al. Oct 2007 A1
20080050737 Arieli et al. Feb 2008 A1
20080064071 Hogrefe et al. Mar 2008 A1
20080146790 Grolz et al. Jun 2008 A1
20080176209 Muller et al. Jul 2008 A1
20080187924 Korfhage et al. Aug 2008 A1
20080227118 Kohno et al. Sep 2008 A1
20080268514 Muller et al. Oct 2008 A1
20080307117 Muller-Cohn et al. Dec 2008 A1
20090010858 Asano Jan 2009 A1
20090226545 Blotsky Sep 2009 A1
20090233283 Rashtchian et al. Sep 2009 A1
20090239208 Mayaudon et al. Sep 2009 A1
20090259023 Su et al. Oct 2009 A1
20090291427 Muller-Cohn et al. Nov 2009 A1
20090298132 Muller-Cohn et al. Dec 2009 A1
20090312285 Fischer et al. Dec 2009 A1
20100099150 Fang et al. Apr 2010 A1
20100159528 Liu et al. Jun 2010 A1
20100159529 Metzler et al. Jun 2010 A1
20100178210 Hogan et al. Jul 2010 A1
20100196904 Arieli et al. Aug 2010 A1
20100261252 Long et al. Oct 2010 A1
20100292447 Pitner et al. Nov 2010 A1
20110014676 Cowan et al. Jan 2011 A1
20110027862 Bates et al. Feb 2011 A1
20110059490 Lagunavicius et al. Mar 2011 A1
20110081363 Whitney et al. Apr 2011 A1
20110111410 Ryan May 2011 A1
20120028933 Baust et al. Feb 2012 A1
20120052572 Whitney et al. Mar 2012 A1
20120100522 Saghbini et al. Apr 2012 A1
20120142070 Battrell et al. Jun 2012 A1
20120149004 Gelfand et al. Jun 2012 A1
20120282634 Hughes et al. Nov 2012 A1
20120295328 Wyrich et al. Nov 2012 A1
20130066234 Helftenbein Mar 2013 A1
20130209997 Whitney et al. Aug 2013 A1
20140017712 Shoji et al. Jan 2014 A1
20140065627 Whitney et al. Mar 2014 A1
20140261474 Gonda Sep 2014 A1
20150329849 Whitney et al. Nov 2015 A1
20160135446 Judy et al. May 2016 A1
20160338342 Whitney et al. Nov 2016 A1
20180352806 Desharnais et al. Dec 2018 A1
Foreign Referenced Citations (120)
Number Date Country
1022441 Dec 1977 CA
2467563 May 2003 CA
101072506 Nov 2007 CN
102026619 Apr 2011 CN
102846541 Jan 2013 CN
102947082 Feb 2013 CN
103384496 Nov 2013 CN
105491883 Apr 2016 CN
2424426 Mar 1975 DE
19834816 Feb 2000 DE
102008029734 Dec 2009 DE
0448146 Sep 1991 EP
0451924 Oct 1991 EP
0493919 Jul 1992 EP
0329822 Jun 1994 EP
0637750 Feb 1995 EP
0706825 Apr 1996 EP
0236069 May 1997 EP
0774464 May 1997 EP
0875292 Nov 1998 EP
0915167 May 1999 EP
1088060 Apr 2001 EP
0833611 Aug 2001 EP
0684315 Jun 2002 EP
0822861 Nov 2003 EP
1555033 Jul 2005 EP
1082006 Feb 2006 EP
0395736 Aug 2006 EP
1736542 Dec 2006 EP
1758932 Mar 2007 EP
1651712 Oct 2007 EP
2934572 Oct 2015 EP
3007556 Apr 2016 EP
3154338 Apr 2017 EP
3155091 Apr 2017 EP
3155395 Apr 2017 EP
2129551 May 1984 GB
S62502633 Oct 1987 JP
H08211065 Aug 1996 JP
H09-87183 Mar 1997 JP
H09127106 May 1997 JP
2000500327 Jan 2000 JP
2001050872 Feb 2001 JP
2009096766 May 2009 JP
4421681 Feb 2010 JP
2012012303 Jan 2012 JP
2012072089 Apr 2012 JP
WO-8607462 Dec 1986 WO
WO-8700196 Jan 1987 WO
WO-8701206 Feb 1987 WO
WO-8900012 Jan 1989 WO
WO-8906542 Jul 1989 WO
WO-9005182 May 1990 WO
WO-9114773 Oct 1991 WO
WO-9200091 Jan 1992 WO
WO-9206188 Apr 1992 WO
WO-9206200 Apr 1992 WO
WO-908349 May 1992 WO
WO-9209300 Jun 1992 WO
WO-9211864 Jul 1992 WO
WO-9206188 Oct 1992 WO
WO 9422885 Oct 1994 WO
WO-9501559 Jan 1995 WO
WO-9502046 Jan 1995 WO
WO-9510605 Apr 1995 WO
WO-9516198 Jun 1995 WO
WO-9610640 Apr 1996 WO
WO-9636436 Nov 1996 WO
WO-9700670 Jan 1997 WO
WO-9705248 Feb 1997 WO
WO-9714785 Apr 1997 WO
WO-9715394 May 1997 WO
WO-9815355 Apr 1998 WO
WO-9824543 Jun 1998 WO
WO 9955346 Nov 1999 WO
WO-9960849 Dec 1999 WO
WO-9967371 Dec 1999 WO
WO-0009746 Feb 2000 WO
WO-0014505 Mar 2000 WO
WO-0020117 Apr 2000 WO
WO-0062023 Oct 2000 WO
WO-0076664 Dec 2000 WO
WO-0137656 May 2001 WO
WO-0194016 Dec 2001 WO
WO-03020874 Mar 2003 WO
WO-03020924 Mar 2003 WO
WO-03056293 Jul 2003 WO
WO-03087335 Oct 2003 WO
WO-2004031363 Apr 2004 WO
WO-2004112476 Dec 2004 WO
WO-2005014704 Feb 2005 WO
WO-2005059178 Jun 2005 WO
WO-2005113147 Dec 2005 WO
WO-2005116081 Dec 2005 WO
WO-2006001499 Jan 2006 WO
WO 2006128022 Nov 2006 WO
WO 2007016352 Feb 2007 WO
WO-2007075253 Jul 2007 WO
WO-2007094581 Aug 2007 WO
WO-2008007463 Jan 2008 WO
WO-2008040126 Apr 2008 WO
WO-2008048228 Apr 2008 WO
WO-2008108549 Sep 2008 WO
WO-2009002568 Dec 2008 WO
WO-2009009210 Jan 2009 WO
WO-2009038853 Mar 2009 WO
WO-2010047592 Apr 2010 WO
WO-2010065924 Jun 2010 WO
WO-2010132508 Nov 2010 WO
WO-2010138522 Dec 2010 WO
WO-2012018638 Feb 2012 WO
WO-2012018639 Feb 2012 WO
WO-2012170907 Dec 2012 WO
WO-2013077290 May 2013 WO
WO-2014049022 Apr 2014 WO
WO-2014100755 Jun 2014 WO
WO-2015002729 Jan 2015 WO
WO-2015191632 Dec 2015 WO
WO-2015191633 Dec 2015 WO
WO-2015191634 Dec 2015 WO
Non-Patent Literature Citations (218)
Entry
“Antibiotics from Prokaryotes.” https://www.boundless.com/microbiology/antimicrobial-drugs/commonly-used-antimicrobial-drugs/antibiotics-from-prokaryotes/, downloaded Aug. 1, 2014.
“Are supplements with amino acid chelated minerals better than those with other forms of minerals?”.
“Borax: Friend or foe?” Momsaware.org webpage, http://www.momsaware.org/household-genera1/139-borax-friend-or-foe.html, downloaded Jul. 31, 2014, 1 page.
“Foods high in glycolic acid.” http://www.ehow.com/list_5815634_foods-high-glycolic-acid.html , downloaded Jul. 31, 2014, 1 page.
“The dose makes the poison.” Yale chemsafe , (http://learn.caim.yale.edu/chemsafe/references/dose.html, downloaded Aug. 1, 2014, 1 page.
Allison et al., “Effects of Drying Methods and Additives on Structure and Function of Actin: Mechanisms of Dehydration-Induced Damage and Its Inhibition,” Archives of Biochemistry and Biophysics 358(1):171-181, 1998.
Anchordoquy et al., “Frontiers in Clinical Research—Preservation of DNA,” Cell Preservation Technology 5(4):180-188, 2007.
Ando et al., “PLGA Microspheres Containing Plasmid DNA: Preservation of Supercoiled DNA via Cryopreparatin and Carbohydrate Stabilization,” Journ. Pharm. Sci., vol. 88, No. 1, pp. 126-130, 1999.
Anonymous, “Transmucosal polymeric molecular delivery systems,” retrieved from http://www.antiagingresearch.com/hgh/transmucosal.php on Apr. 7, 2005, 2 pages.
Arakawa et al., “Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs,” Biochimica et Biophysica Acta 1764:1677-1687, 2006.
Asano, “Glycosidase inhibitors: update and perspectives on practical use,” Glycobiology 13(10):93R-104R, 2003.
Balevicius et al., NMR and quantum chemistry study of mesoscopic effects in ionic liquids. J.Phys.Chem., 114:5365-5371, 2010.
Barnes, The fidelity of Taq polymerase catalyzing PCR is improved by an N-terminal deletion. Gene, 112:29-35, 1992.
Baskakov et al., “Forcing Thermodynamically Unfolded Proteins to Fold,” The Journal of Biological Chemistry, 273(9):4831-4834, 1998.
Boyd et al., “Stabilization Effect of Polyvinyl Alcohol on Horseradish Peroxidase, Glucose Oxidase, 13-Galactosidase and Alkaline Phosphatase,” Biotechnology Techniques 10(9):693-698, 1996.
Braasch et al. Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem Bio 8:1-7, 2001.
Branco et al., Preparation and characterization of new room temperature ionic liquids. Chem.Eur.J. 8:16, p. 3671-3677, 2002.
Buhler et al., “Viral Evolution in Response to the Broad-Based Retroviral Protease Inhibitor TL-3,” Journal of Virology 75(19):9502-9508, 2001.
Calfon et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 415:92-96, 2002. (Abstract only).
Carninci et al., “Thermostabilization and thermoactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA,” Proc. Natl. Acad. Sci. USA 95:520-524, 1998.
Carpenter et al., “Stabilization of phosphofructokinase during air-drying with sugars and sugar/transition metal mixtures,” Cryobiology 24(5): 455-464, 1987. (Abstract).
Catalan et al., “Progress towards a generalized solvent polarity scale: The solvatochromism of 2-(dimethylamino)-7-nitrofluorene and its homomorph 2-fluoro-7-nitrofluorene”, Liebigs Ann. 1995(2):241-252, 1995.
Catalan, Solvent effects based on pure solvent scales. In: Handbook of Solvents. Wypych G., ed. Toronto: ChemTec Publishing and New York: William Andrew Publishing. p. 583-616, 2001.
Cavalieri et al., “Chaperone-like activity of nanoparticles of hydrophobized poly(vinyl alcohol),” Soft Matter 3:718-724, 2007.
Chen et al., “Stabilization of Recombinant Human Keratinocyte Growth Factor by Osmolytes and Salts,” Journal of Pharmaceutical Sciences, 85(4):419-426, 1996.
Cheng et al., “Chip PCR. II. Investigation of different PCR amplification systems in microfabricated silicon-glass chips,” Nucleic Acids Res. 24:380-385, 1996.
Clement et al. Bioactive isomalabaricane triterpenoids from Rhabdastrella globostellata that stabile the binding of DNA polymerase beta to DNA. J. Nat. Prod., 69(3):373-6, 2006.
Clement et al., Following nature's lead: Generating compounds for stabilizing biomolecules. Biopreservation and Biobanking, 10(4):395-402, 2012.
Cohen et al., “Diffusion NMR Spectroscopy in Supramolecular and Combinatorial Chemistry: An Old Parameter—New Insights,” Angew. Chem. Int. Ed., 44: 520-554, 2005.
Dagani, “Stir, Heat—But No Need to Dissolve,” Chemical & Engineering News 81(5): 3 pages, 2003.
Dankwardt et al., “Stabilization of enzyme immunoassays for atrazine,” Analytica Chimica Acta 362:35-45, 1998.
Daugherty et al., “Formulation and delivery issues for monoclonal antibody therapeutics,” Advanced Drug Delivery Reviews 58:686-706, 2006.
De Sanctis et al., “Influence of Glycerol on the Structure and Redox Properties of Horse Heart Cytochrome c. A Circular Dichroism and Electrochemical Study,” Journal of Protein Chemistry, 15(7):599-606, 1996.
Degim et al., “Controlled Delivery of Peptides and Proteins,” Current Pharmaceutical Design 13:99-117, 2007.
Del Vigna de Almeida et al., Saliva composition and functions: A comprehensive review. The Journal of Contemporary Dental Practice, 9(3):72-80, 2008.
DePaz et al., “Effects of drying methods and additives on the structure, function, and storage stability of subtilisin: role of protein conformation and molecular mobility,” Enzyme and Microbial Technology 31:765-774, 2002.
Di Tullio et al., “Molecular recognition by mass spectrometry,” J. Mass Spectrom, 40(7):845-865, 2005.
DNA learning center, “Radiation can cause DNA mutations, 3D animation with narration.” http://www.dnalc.org/view/15529-Radiation-can-cause-DNA-mutations-3D-animation-with-narration.html, downloaded Aug. 1, 2014.
Dong et al., “Biosynthesis of the Validamycins: Identification of Intermediates in the Biosynthesis of Validamycin A by Streptomyces hygroscopicus var. limoneus,” J. Am. Chem. Soc. 123:2733-2742, 2001.
Dowell et al. Otitis media—principles of judicious use of antimicrobial agents. Pedatrics. 101 Suppl. 1: 165-171, 1998.
Dowell et al. Principles of judicious use of antimicrobial agents for pediatric upper respiratory tract infections. Pedatrics. 101 Suppl. 1: 163-165, 1998.
Dyke et al., “Solvent-Free Functionalization of Carbon Nanotubes,” J. Am. Chem. Soc. 125:1156-1157, 2003.
El-Bashiti, “Trehalose Metabolism in Wheat and Identification of Trehalose Metabolizing Enzymes Under Abiotic Stress Conditions,” Thesis, The Graduate School of Natural and Applied Sciences of the Middle East Technical University, Jul. 2003, 140 pages.
Ellison et al., Buffer capacities of human blood and plasma. Clinical Chemistry, 4(6):452-461, 1958.
Elzie et al., “The N-terminus of thrombospondin: the domain stands apart,” The International Journal of Biochemistry & Cell Biology 36:1090-1101, 2004.
EP05778182.5 Office Action dated Apr. 28, 2010.
EP06848927.7 Office Action dated Jan. 20, 2009.
EP06848927.7 Office Action dated May 3, 2010.
EP06848927.7 Office Action dated Nov. 30, 2010.
EP08826300.9 Supplementary Search Report dated Oct. 26, 2010.
EP10775442.6 Extended European Search Report dated Jan. 21, 2014.
EP11815081.2 Communication dated Jan. 4, 2016.
EP11815081.2 Extended European Search Report dated Nov. 5, 2013.
EP11815081.2 Office Action dated Jan. 15, 2015.
EP11815082.0 Communication dated Jan. 4, 2016.
EP11815082.0 Extended European Search Report dated Nov. 5, 2013.
EP11815082.0 Office Action dated Jan. 15, 2015.
EP13865767.1 extended European Search Report dated Oct. 24, 2016.
EP14819510.0 extended European Search Report dated Feb. 7, 2017.
EP14819510.0 partial supplementary European Search Report dated Nov. 4, 2016.
Extended EP Search Report, EP Patent Application No. 21188996.9, mailed Jan. 5, 2022, 9 pages.
Flaman et al., A rapid PCR fidelity assay. Nucleic Acids Research, 22(15): 3259-3260, 1994.
Frye et al., “The kinetic basis for the stabilization of staphylococcal nuclease by xylose,” Protein Science, 6:789-793, 1997.
Galinski et al., “1,4,5,6-Tetrahydro-2-methyl-4-pyrimidinecarboxylic acid. A novel cyclic amino acid from halophilic phototrophic bacteria of the genus Ectothiorhodospira,” Eur. J. Biochem., 149:135-139, 1985.
Garcia de Castro et al., “Anhydrobiotic Engineering of Gram-Negative Bacteria,” Applied and Environmental Microbiology 66(9):4142-4144, 2000.
Gerard et al., cDNA synthesis by moloney murine leukemia virus RNase H-minus reverse transcriptase possessing full DNA polymerase activity. Focus, 14(1): 91-93, 1992.
Godfrey, “Solvent selection via miscibility number,” Chem. Technol. 2(6):359-363, 1972.
Goller et al., Protection of a model enzyme (lactate dehydrogenase) against heat, urea and freeze-thaw treatment by compatible solute additives, J. of Molecular Catalsys B: Enzymatic, 7(104):37-45, 1999.
Gombotz et al., “Biodegradable Polymers for Protein and Peptide Drug Delivery,” Bioconjugate Chem. 6:332-351, 1995.
Gowrishankar et al., Osmoregulation in Enterobacteriaceae: Role of proline/Betaine transport systems. Current Science, 57(5): 225-234, 1988.
Green DR, “Apoptosis. Death deceiver,” Nature, 396(6712):629-30, 1998.
Green DR, “Apoptotic pathways: the roads to ruin,” Cell, 94(6):695-69, 1998.
Green et al., “Mitochondria and apoptosis,” Science, 281(5381):1309-12, 1998.
Harding et al., Perk Is Essential for Translational Regulation and Cell Survival during the Unfolded Protein Response. (2000) Mol Cell 5:897-904.
Haze et al., Mammalian Transcription Factor ATF6 Is Synthesized as a Transmembrane Protein and Activated by Proteolysis in Response to Endoplasmic Reticulum Stress. Mol Biol Cell 10(11):3787-3799, 1999.
Henke et al., Betaine improves the PCR amplification of GC-rich DNA sequences. Nucleic Acids Research, 25(19): 3957-3958, 1997.
Hewetson et al., Sucrose concentration in blood: A new method for assessment of gastric permeability in horses with gastric ulceration. J.Vet.Inter.Med., 20:388-394, 2006.
Hoffman, “Hydrogels for biomedical applications,” Advanced Drug Delivery Reviews 43:3-12, 2002.
Holland et al., “Biological sample collection and processing for molecular epidemiological studies,” Mutation Research 543:217-234, 2003.
Holland et al., “Molecular epidemiology biomarkers—Sample collection and processing considerations,” Toxicology and Applied Pharmacology 206:261-268, 2005.
Houts et al., Reverse transcriptase from avian myeloblastosis virus. Journal of Virology, 29(2): 517-522, 1979.
https://www.consumerlab.com/answers/Are+supplements+with+amino+acid+chelated+minerals+better+than+those+with+other+forms+of+minerals%3F/amino_acid_mineral_chelates/, downloaded Jul. 31, 2014, 1 page.
Iyer et al., Enzyme stability and stabilization-Aqueous and non-aqueous environment, Process Biochemistry, 43:1019-1032, 2008.
Jin et al., Effect of mobile phase additives on resolution of some nucleic compounds in high performance liquid chromatography. Biotechnology and Bioprocess Engineering, 12:525-530, 2007.
Jones et al., “Long-term storage of DNA-free RNA for use in vaccine studies,” BioTechniques 43(5):675-681, 2007.
Kaijalainen et al., “An alternative hot start technique for PCR in small volumes using beads of wax-embedded reaction components dried in trehalose,” Nucleic Acids Research 21(12):2959-2960, 1993.
Kameda et al., “New Cyclitols, Degradation of Validamycin A by Flavobacterium Saccharophilum,” The Journal of Antibiotics 33(12):1573-1574, 1980.
Kaufman. Orchestrating the unfolded protein response in health and disease. J Clin Invest 110(10):389-1398, 2002.
Kilger and Paabo, Direct DNA sequence determination from total genomic DNA. Nucleic Acids Research, 25(10): 2032-2034, 1997.
Kim et al., Chemical Biology Investigation of Cell Death Pathways Activated by Endoplasmic Reticulum Stress Reveals Cytoprotective Modulators of ASK1S. J. Biol. Chem. 284(3):1593-1603, 2009.
Kirn-Safran et al., “Heparan Sulfate Proteoglycans: Coordinators of Multiple Signaling Pathways during Chondrogenesis,” Birth Defects Research (Part C) 72:69-88, 2004.
Knapp et al., “Extrinsic protein stabilization by the naturally occurring osmolytes β-hydroxyectoine and betaine,” Extremophiles, 3:191-198, 1999.
Knuesel et al., “Comparative studies of suidatrestin, a specific inhibitor of trehalases,” Comparative Biochemistry and Physiology Part B 120:639-646, 1998.
Komiyama et al., “Hydrolysis of DNA and RNA by lanthanide ions: mechanistic studies leading to new applications,” Chem. Commun.: 1443-1451, 1999.
Konishi et al., “Effects of Bay m 1099, an a-Glucosidase Inhibitor, on Starch Degradation in Germinating Mung Beans,” Biosci. Biotechnol. Biochem. 62(1):142-144, 1998.
Kotewicz et al., Isolation of closed Moloney murine leukemia virus reverse transcriptase lacking ribonuclease H activity. Nucleic Acid Research, 16(1):265, 1988.
Kravitz, Lactate: Not guilty as charged. IDEA Fitness Journal 2(6), 23-25, 2005 http://www.unm.edu/lkravitz/Article/%20folder/lactate.html, 3d paragraph, downloaded Jul. 31, 2014.
Kricka and Wilding, “Microchip PCR,” Anal. Bioanal. Chem 377:820-825, 2003.
Kudo et al., A molecular chaperone inducer protects neurons from ER stress. Cell Death and Differentiation, 15:364-375, 2008.
Kumar et al., “The role of proline in the prevention of aggregation during protein folding in vitro,” Biochemistry and Molecular Biology International, 46(3):509-517, 1998.
Langer, “Polymer-Controlled Drug Delivery Systems,” Acc. Chem. Res. 26:537-542, 1993.
Langer. New methods of drug delivery. Science, New Series, vol. 249, No. 4976, pp. 1527-1533, 1990.
Lawyer et al., High-level expression, purification, and enzymatic characterization of full-length Thermus aquaticus DNA polymerase and a truncated form deficient in 5′ to 3′ exonuclease activity. PCR Methods and Applications, Cold Spring Harbor Laboratory Press, 2:275-287, 1993.
Lee et al., “Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: Development of a broad-based protease inhibitor efficacious against FIV, SW, and HIV in vitro and ex vivo,” Proc. Natl. Acad. Sci. USA 95:939-944, 1998.
Lee et al., “Development of a New Type of Protease Inhibitors, Efficacious against FIV and HIV Variants,” J. Am. Chem. Soc. 121:1145-1155, 1999.
Li et al., “Effect of Mobile Phase Additives on the Resolution of Four Bioactive Compounds by RP-HPLC”, Int'l Journal of Molecular Sciences, 11(5):2229-2240, 2010.
Liao et al., “The effects of polyvinyl alcohol on the in vitro stability and delivery of spray-dried protein particles from surfactant-free HFA 134a-based pressurised metered dose inhalers,” International Journal of Pharmaceutics 304:29-39, 2005.
Loo et al., Peptide and Protein Analysis by Electrospray Ionization—MassSpectrometry and Capillary Electrophoresis-Mass Spectrometry, Anal. Biochem., 179(2):404-412, 1989.
Lou et al., “Increased amplification efficiency of microchip-based PCR by dynamic surface passivation,” Biotechniques, vol. 36, No. 2, pp. 248-252, 2004.
Lozano et al., Stabilization of x-Chymotrypsin by iconic liquids in transesterification reactions. Biotechnology and Bioengineerig, 75(5):563-569, 2001.
Luo et al., “Expression of a fusion protein of scFv-biotin mimetic peptide for immunoassay,” J. Biotechnol. 65:225, 1998.
Malin et al., “Effect of Tetrahydropyrimidine Derivatives on Protein-Nucleic Acids Interaction,” The Journal of Biological Chemistry, 274(11):6920-6929, 1999.
Manzanera et al., “Hydroxyectoine Is Superior to Trehalose for Anhydrobiotic Engineering of Pseudomanas putida KT2440,” Applied and Environmental Microbiology 68(9):4328-4333, 2002.
Manzanera et al., “Plastic Encapsulation of Stabilized Escherichia coli and Pseudomonas putida,” Applied and Environmental Microbiology 70(5):3143-3145, 2004.
Marshall et al.,“NXY-059, a Free Radical-Trapping Agent, Substantially Lessens the Functional Disability Resulting From Cerebral Ischemia in a Primate Species,” Stroke, 32:190-198 (2001).
Mascellani et al., “Compatible solutes from hyperthermophiles improve the quality of DNA microarrays,” BMC Biotechnology, 7(82):1-6, 2007.
Mitchell et al., “Dispersion of Functionalized Carbon Nanotubes in Polystyrene,” Macromolecules 35:8825-8830, 2002.
Mizuguchi et al., Characterization and application to hot start PCR of neutralizing momoclonal antibodies against KOD DNA polymerase. J. Biochem., 126:762-768, 1999.
Mohr, “Reversible chemical reactions as the basis for optical sensors used to detect amines, alcohols and humidity,” J. Mater. Chem., 9:2259-2264, 1999.
Mori K, Tripartite Management Mini review of Unfolded Proteins in the Endoplasmic Reticulum. Cell 101(5):451-454, 2000.
Natale et al., Sensitivity of Bovine Blastocyst Gene Expression Patterns to Culture Environments Assessed by Differential Display RT-PCR. Reproduction, 122 (5): 687-693, 2001.
New England Biolabs 1993/1994, 4 pages.
Nielsen et al., Peptide nucleis acid (PNA). A DNA mimic with a peptide backbone. Bioconjugate Chemistry, 5:3-7, 1994.
O'Brien et al. Acute sinusitis—principles of judicious use of antimicrobial agents. Pedatrics. 101 Suppl. 1: 174-177, 1998.
O'Brien et al. Cough illness/bronchitis—principles of judicious use of antimicrobial agents. Pedatrics. 101 Suppl. 1: 178-181, 1998.
Okada et al. Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. Biochem J 366(Pt 2):585-594, 2002.
Ortega et al., “New functional roles for non-collagenous domains of basement membrane collagens,” Journal of Cell Science 115:4201-4214, 2002.
Parsegian et al., “Macromolecules and Water: Probing with Osmotic Stress,” Methods in Enzymology, 259:43-94, 1995.
Passot et al., “Physical characterization of formulations for the development of two stable freeze-dried proteins during both dried and liquid storage,” European Journal of Pharmaceutics and Biopharmaceutics 60:335-348, 2005.
Pavlov et al., “The Role of ECM Molecules in Activity-Dependent Synaptic Development and Plasticity,” Birth Defects Research (Part C) 72:12-24, 2004.
PCT/US2005/012084 International Preliminary Report on Patentability dated Oct. 11, 2006.
PCT/US2005/012084 International Search Report dated Feb. 7, 2006.
PCT/US2006/45661 International Preliminary Report on Patentability dated Jun. 30, 2008.
PCT/US2006/45661 International Search Report and Written Opinion dated Nov. 13, 2007.
PCT/US2008/061332 International Preliminary Report on Patentability dated Oct. 27, 2009.
PCT/US2008/061332 International Search Report and Written Opinion dated Jul. 29, 2009.
PCT/US2008/068628 International Preliminary Report on Patentability dated Jan. 5, 2010.
PCT/US2008/068628 International Search Report and Written Opinion dated Aug. 27, 2009.
PCT/US2010/34454 International Preliminary Report on Patentability dated Nov. 15, 2011.
PCT/US2010/34454 International Search Report and Written Opinion dated Jan. 20, 2011.
PCT/US2011/045404 International Preliminary Report on Patentability dated Jan. 29, 2013.
PCT/US2011/045404 International Search Report and Written Opinion dated Mar. 27, 2012.
PCT/US2011/045405 International Preliminary Report on Patentability dated Jan. 29, 2013.
PCT/US2011/045405 International Search Report and Written Opinion dated Mar. 26, 2012.
PCT/US2013/077290 International Preliminary Report on Patentability mailed Jul. 2, 2015.
PCT/US2013/077290 International Search Report and Written Opinion mailed Jun. 23, 2014.
PCT/US2014/041396 International Search Report mailed Mar. 13, 2015.
PCT/US2014/042396 International Preliminary Report on Patentability mailed Dec. 23, 2015.
PCT/US2014/042396 Written Opinion mailed Mar. 13, 2015.
PCT/US2015/034967 International Search Report and Written Opinion dated Sep. 8, 2015.
PCT/US2015/034968 International Search Report and Written Opinion Mailed Sep. 16, 2015.
PCT/US2015/034969 International Preliminary Report on Patentability dated Dec. 22, 2016.
PCT/US2015/034969 International Search Report and Written Opinion dated Sep. 15, 2015.
PCT/US2016/065198 International Search Report and Written Opinion dated Mar. 13, 2017.
PCT/US2016/065200 International Search Report and Written Opinion dated Feb. 16, 2017.
Peters et al., Sensitivity of human, murine, and rat cells to 5-Fluorouracil and 5′-Deoxy-5-fluorounidine in relation to drug-metabolizing enzymes Cancer Research, 46:20-28, 1986.
Pickering, LK, Ed. Red Book: Report of the Committee on Infectious Diseases, 26th edition. Elk Grove Village, IL, pp. 695-697, 2003.
Prestrelski et al., “Dehydration induced Conformational Transitions in Proteins and Their Inhibition by Stabilizers,” Biophysical Journal 65:661-671, 1993.
Qu et al., Ambient stable quantitative PCR reagents for the detection of Yersinia pestis. PLoS Neglected Tropical Diseases, 4(3):e629, 2010.
Roberts, “Organic compatible solutes of halotolerant and halophilic microorganisms,” Saline Systems, 1(5):1-30, 2005.
Roche. “PCR Reaction Components.” Downloaded from the internet (http://www.roche-appliedscience.com/sis/amplification/pcr_amplification_050300.html; Downloaded on Dec. 13, 2012, 4 pages.
Ron and Walter, Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 8:519-529, 2007 (Abstract only).
Rosenstein et al. The common cold—principles of judicious use of antimicrobial agents. Pediatrics. 101 Suppl. 1: 181-184., 1998.
Sadeghi et al., Effect of alkyl chain length and temperature on the thermodynamic properties of ionic liquids 1-alkyl-3-methylimidazolium bromide in aqueous and non-aqueous solutions at different temperatures. J.Chem.Thermodynamics, 41:273-289, 2009.
Saiki et al. Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase. Science 239:487-491, 1988.
Sauer et al., “Bacterial Milking: A Novel Bioprocess for Production of Compatible Solutes,” Biotechnology and Bioengineering, 57(3):306-313, 1998.
Sawicki, “Foods high in Glutathione.” http://www.ehow.com/list_6900955_foods-high-glutathione.html, downloaded Jul. 31, 2014, 1 page.
Schnoor, et al. Characterization of the synthetic compatible solute homoectoine as a potent PCR enhancer. Biochem and Biophys. Res. Comm, 322:867-872, 2004.
Schwartz et al. Pharyngitis—principles of judicious use of antimicrobial agents. Pedatrics. 101 Suppl. 1: 171-174, 1998.
Schyma et al., “DNA-PCR Analysis of Bloodstains Samples by the Polyvinyl-Alcohol Method,” Journal of Forensic Sciences 44(1):95-99, 1999.
Schyma et al., “The Accelerated Polyvinyl-Alcohol Method for GSR Collection—PVAL 2.0,” Journal of Forensic Sciences 45(6):1303-1306, 2000.
Schyma, “Erfahrungen mit der PVAL—Methode in der rechtsmedizinischen Praxis,” Arch. Kriminol. /97(1-2):41-46, 1996.
Scouten, “A survey of enzyme coupling techniques,” Methods in Enzymology, 135:30-65, 1987.
Sigma Catalog. St. Louis:Sigma-Aldrich. p. 1987, 1998.
Sirieix-Plenet et al., “Behaviour of a binary solvent mixture constituted by an amphiphilic ionic liquid, 1-decy1-3-methylimidazolium bromide and water Potentiometric and conductimetric studies,” Talanta 63(4):979-986, Jul. 8, 2004.
Slita et al., “DNA-polycation complexes Effect of polycation structure on physico-chemical and biological properties,” Journal of Biotechnology, 127:679-693, 2007.
Smith et al., “Optimal Storage Conditions for Highly Dilute DNA Sampled: A Role for Trehalose as a Preserving Agent,” Journal of Forensic Science 50(5):1-8, 2005.
Sola-Penna et al., “Carbohydrate protection of enzyme structure and function against guanidinium chloride treatment depends on the nature of carbohydrate and enzyme,” Eur. J. Biochem., 248:24-29, 1997.
Soltis and Skalka, The alpha and beta chains of avian retrovirus reverse transcriptase independently expressed in Escherichia coli: Characterization of enzymatic activities. Proc. Nat. Acad. Sci. USA, 85:3372-3376, 1968.
Spiess et al., Trehalose is a potent PCR enhancer: Lowering of DNA melting temperature and thermal stabilization of Taq polymerase by the disaccharide trehalose. Clinical Chemistry, 50:1256-1259, 2004.
Stein and Moore, The free amino acids of human blood plasma. JCB, 211:915-926, 1954.
Stock et al., Effects of ionic liquids on the acetylcholinesterase—A structure-activity relationship consideration. Green Chemistry, 6:286-290, 2004.
Suslick et al., “Colorimetric sensor arrays for molecular recognition,” Tetrahedron 60:11133-11138, 2004.
The Frontier energy solution, Inc.'s FAQ, http://www.frontierenergysolutionsinc.com/faq/, downloaded Jul. 31, 2014, 1 page.
Timasheff, “Water as Ligand: Preferential Binding and Exclusion of Denaturants in Protein Unfolding,” Biochemistry, 3/(40:9857-9864, 1992.
U.S. Appl. No. 11/291,267 Office Action dated Jun. 13, 2014.
U.S. Appl. No. 12/182,926 Office Action dated Apr. 30, 2014.
U.S. Appl. No. 13/191,346 Office Action dated Jul. 22, 2014.
U.S. Appl. No. 11/102,588 Notice of Allowance mailed Sep. 24, 2014.
U.S. Appl. No. 11/291,267 Office Action dated Mar. 12, 2015.
U.S. Appl. No. 12/509,303 Office Action dated Jun. 9, 2014.
U.S. Appl. No. 13/191,346 Office Action dated Jul. 2, 2015.
U.S. Appl. No. 13/191,346 Office Action dated Mar. 20, 2015.
U.S. Appl. No. 13/812,288 Office Action dated Aug. 25, 2016.
U.S. Appl. No. 13/812,288 Office Action dated Feb. 1, 2017.
U.S. Appl. No. 13/812,288 Office Action dated Feb. 11, 2016.
U.S. Appl. No. 13/812,288 Office Action dated Jan. 12, 2017.
U.S. Appl. No. 13/812,288 Office Action dated May 7, 2015.
U.S. Appl. No. 13/812,288 Restriction Requirement dated Oct. 9, 2014.
U.S. Appl. No. 13/966,117 Final Office Action dated Feb. 26, 2015.
U.S. Appl. No. 13/966, 117 Office Action dated Sep. 25, 2014.
U.S. Appl. No. 14/895,475 Office Action dated Jan. 10, 2017.
U.S. Appl. No. 14/895,475 Office Action dated May 22, 2017.
Vanin, “Iron diethyldithiocarbamate as spin trap for nitric oxide detection,” Meth. Enzymol., 301:269-79 (1999).
Voziyan et al., “Chaperonin-assisted folding of glutamine synthetase under nonpermissive conditions: Off-pathway aggregation propensity does not determine the co-chaperonin requirement,” Protein Science, 9:2405-2412, 2000.
Wang et al., “A Naturally Occurring Protective System in Urea-Rich Cells: Mechanism of Osmolyte Protection of Proteins against Urea Denaturation,” Biochemistry, 36:9101-9108, 1997.
Wang et al., “Antibody Structure, Instability, and Formulation,” Journal of Pharmaceutical Sciences 96(1):1-26, 2007.
Wang et al., “Instability, stabilization, and formulation of liquid protein pharmaceuticals,” International Journal of Pharmaceutics 185:129-188, 1999.
Wang, “Protein aggregation and its inhibition in biopharmaceutics,” International Journal of Pharmaceutics 289:1-30, 2005.
Whitman et al., “Prokaryotes: the unseen majority,” Proc. Natl. Acad. Sci. USA, 95:6578-83, 1998.
Whittlesey et al., “Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface,” Experimental Neurology 190:1-16, 2004.
Wierzbicka-Patynowski et al., “The ins and outs of fibronectin matrix assembly,” Journal of Cell Science 116:3269-3276, 2003.
Yamamoto et al., “Molecular Design of Bioconjugated Cell Adhesion Peptide with a Water-Soluble Polymeric Modifier for Enhancement of Antimetastatic Effect,” Current Drug Targets 3:123-130, 2002.
Yancey et al., “Living with Water Stress: Evolution of Osmolyte Systems,” Science, 217:1214-1222, 1982.
Yang et al., Neuroprotection by 2-h postischemia administration of two free radical scavengers, alpha-phenyl-n-tert-butyl-nitrone (PBN) and N-tert-butyl-(2-sulfophenyl)-nitrone (S-PBN), in rats subjected to focal embolic cerebral ischemia., Exp. Neurol., 163(1):39-45, 2000.
Yoshida et al., Identification of the cis-Acting Endoplasmic Reticulum Stress Response Element Responsible for Transcriptional Induction of Mammalian Glucose-regulated Proteins: Involvement of basic leucine zipper transcription factors. J Biol Chem 273:33741-33749, 1998.
Zhao et al., “NXY-059, a novel free radical trapping compound, reduces cortical infarction after permanent focal cerebral ischemia in the rat,” Brain Res., 909(1-2):46-50, 2001.
Zhi et al., “Renaturation of citrate synthase: Influence of denaturant and folding assistants,” Protein Science, 1:522-529, 1992.
Related Publications (1)
Number Date Country
20230363375 A1 Nov 2023 US
Provisional Applications (1)
Number Date Country
62010151 Jun 2014 US
Continuations (3)
Number Date Country
Parent 16931698 Jul 2020 US
Child 18202419 US
Parent 16049516 Jul 2018 US
Child 16931698 US
Parent 15316677 US
Child 16049516 US